About the Company
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ACRX News
Recap: AcelRx Pharmaceuticals Q1 Earnings
AcelRx Pharmaceuticals (NASDAQ:ACRX) reported its Q1 earnings results on Wednesday, May 10, 2023 at 04:05 PM. Here's what investors need to know about the announcement. AcelRx Pharmaceuticals beat ...
AcelRx Pharmaceuticals
A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...
AcelRx Pharma plans IPO of about 5.8 M shares
Please purchase an Enhanced Subscription to continue reading. To continue, please log in, or sign up for a new account. We offer one free story view per month. If you ...
Talphera (TLPH) Price Target Increased by 10.81% to 5.23
Talphera Background Information (This description is provided by the company.) acelrx pharmaceuticals inc. is a specialty ...
AcelRx Pharmaceuticals Inc (R5XA.BE)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Daniel Janney's Net Worth
Daniel Janney has an estimated net worth of $440 Million. This is based on reported shares across multiple companies, which include IMMUNE DESIGN CORP., ZS Pharma, Inc., SUTRO BIOPHARMA, INC ...
Marina Bozilenko's Net Worth
Marina Bozilenko does not have any significant net worth to report based on the numbers we have. This is based on reported shares in ACELRX PHARMACEUTICALS INC.
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical ...
Biomarin Pharmaceutical Inc BMRN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...